Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. [electronic resource]
Producer: 20190826Description: 95-101 p. digitalISSN:- 1095-6859
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Diamines -- administration & dosage
- Female
- Humans
- Kaplan-Meier Estimate
- MAP Kinase Kinase Kinases -- antagonists & inhibitors
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Phosphoinositide-3 Kinase Inhibitors
- Progression-Free Survival
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- Pyrazoles -- administration & dosage
- Pyridones -- administration & dosage
- Pyrimidinones -- administration & dosage
- Signal Transduction -- drug effects
- Uterine Cervical Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.